Published in Cancer Res on January 15, 2006
Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest (2008) 7.52
How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature (2012) 3.77
Cancer associated fibroblasts: the dark side of the coin. Am J Cancer Res (2011) 2.26
Fibroblast heterogeneity in the cancer wound. J Exp Med (2014) 2.09
Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (Landmark Ed) (2010) 1.87
Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells: implications for preventing chemotherapy resistance. Cancer Biol Ther (2011) 1.85
Genetic instability caused by loss of MutS homologue 3 in human colorectal cancer. Cancer Res (2008) 1.81
Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. Breast Cancer Res (2011) 1.80
Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch (2008) 1.71
Role of monocarboxylate transporters in human cancers: state of the art. J Bioenerg Biomembr (2012) 1.70
An analogy between the evolution of drug resistance in bacterial communities and malignant tissues. Nat Rev Cancer (2011) 1.58
Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review). Oncol Lett (2012) 1.58
Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol (2010) 1.54
Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS One (2012) 1.53
Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance. Drug Resist Updat (2008) 1.49
Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy. Clin Cancer Res (2011) 1.46
Wnt signaling directs a metabolic program of glycolysis and angiogenesis in colon cancer. EMBO J (2014) 1.43
Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments. Dis Model Mech (2011) 1.35
Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer (2011) 1.34
pH sensing and regulation in cancer. Front Physiol (2013) 1.33
Expression of monocarboxylate transporters 1, 2, and 4 in human tumours and their association with CD147 and CD44. J Biomed Biotechnol (2010) 1.32
PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer. Br J Cancer (2008) 1.27
Hyaluronan, CD44, and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells. Cancer Res (2009) 1.26
Cancer-stromal interactions: role in cell survival, metabolism and drug sensitivity. Cancer Biol Ther (2011) 1.20
Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer. Cell Cycle (2013) 1.14
Tumour-stroma interactions in colorectal cancer: converging on beta-catenin activation and cancer stemness. Br J Cancer (2008) 1.13
Epithelial and mesenchymal tumor compartments exhibit in vivo complementary patterns of vascular perfusion and glucose metabolism. Neoplasia (2007) 1.12
Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression. Clin Exp Metastasis (2010) 1.09
Extracellular vesicles from bone marrow mesenchymal stem/stromal cells transport tumor regulatory microRNA, proteins, and metabolites. Oncotarget (2015) 1.07
Differential expression of metabolic genes in tumor and stromal components of primary and metastatic loci in pancreatic adenocarcinoma. PLoS One (2012) 1.05
The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. Ann Oncol (2014) 1.03
Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H(+) symporters. J Mol Med (Berl) (2015) 1.02
Metabolism addiction in pancreatic cancer. Cell Death Dis (2014) 1.02
Expression and significance of hypoxia-inducible factor-1α and glucose transporter-1 in laryngeal carcinoma. Oncol Lett (2012) 1.01
Cancer-associated fibroblasts from hepatocellular carcinoma promote malignant cell proliferation by HGF secretion. PLoS One (2013) 1.00
Cholesteatoma fibroblasts promote epithelial cell proliferation through overexpression of epiregulin. PLoS One (2013) 0.99
Lactate is a mediator of metabolic cooperation between stromal carcinoma associated fibroblasts and glycolytic tumor cells in the tumor microenvironment. Exp Cell Res (2011) 0.99
Metabolic alterations in lung cancer-associated fibroblasts correlated with increased glycolytic metabolism of the tumor. Mol Cancer Res (2013) 0.97
A digest on the role of the tumor microenvironment in gastrointestinal cancers. Cancer Microenviron (2010) 0.97
p53 Protects lung cancer cells against metabolic stress. Int J Oncol (2010) 0.96
Stromal cells and integrins: conforming to the needs of the tumor microenvironment. Neoplasia (2009) 0.95
Hereditary ovarian cancer and two-compartment tumor metabolism: epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NFκB activation in the tumor stroma. Cell Cycle (2012) 0.95
Hypoxia-inducible factor 1 alpha expression increases during colorectal carcinogenesis and tumor progression. BMC Cancer (2008) 0.94
The chemistry, physiology and pathology of pH in cancer. Philos Trans R Soc Lond B Biol Sci (2014) 0.94
Hepatocellular carcinoma: Review of disease and tumor biomarkers. World J Hepatol (2016) 0.94
Endothelial cell metabolism and implications for cancer therapy. Br J Cancer (2012) 0.93
The metabolic interactions between tumor cells and tumor-associated stroma (TAS) in prostatic cancer. Cancer Biol Ther (2012) 0.93
A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer. BMC Cancer (2014) 0.93
Expression and activity of carbonic anhydrase IX is associated with metabolic dysfunction in MDA-MB-231 breast cancer cells. Cancer Invest (2009) 0.92
EPR oxygen imaging and hyperpolarized 13C MRI of pyruvate metabolism as noninvasive biomarkers of tumor treatment response to a glycolysis inhibitor 3-bromopyruvate. Magn Reson Med (2012) 0.90
Mitochondrial biogenesis drives tumor cell proliferation. Am J Pathol (2011) 0.90
Mitochondria and cancer: past, present, and future. Biomed Res Int (2013) 0.90
Changing the energy of an immune response. Am J Clin Exp Immunol (2013) 0.88
Lactate dehydrogenase-B is silenced by promoter methylation in a high frequency of human breast cancers. PLoS One (2013) 0.88
Fibroblasts--a key host cell type in tumor initiation, progression, and metastasis. Ups J Med Sci (2012) 0.88
The colon cancer stem cell microenvironment holds keys to future cancer therapy. J Gastrointest Surg (2014) 0.88
Cancer-associated fibroblasts in digestive tumors. World J Gastroenterol (2014) 0.87
Enhancement of head and neck squamous cell carcinoma proliferation, invasion, and metastasis by tumor-associated fibroblasts in preclinical models. Head Neck (2013) 0.87
Monocarboxylate transporters 1-4 in NSCLC: MCT1 is an independent prognostic marker for survival. PLoS One (2014) 0.87
Regulation of metastasis in colorectal adenocarcinoma: a collision between development and tumor biology. Surgery (2008) 0.87
Cancer-associated fibroblasts connect metastasis-promoting communication in colorectal cancer. Front Oncol (2015) 0.87
Cancer-associated stroma affects FDG uptake in experimental carcinomas. Implications for FDG-PET delineation of radiotherapy target. Eur J Nucl Med Mol Imaging (2008) 0.86
Relationships between LDH-A, lactate, and metastases in 4T1 breast tumors. Clin Cancer Res (2013) 0.86
Mechanistic insights into self-reinforcing processes driving abnormal histogenesis during the development of pancreatic cancer. Am J Pathol (2013) 0.86
Characterization of monocarboxylate transporters (MCTs) expression in soft tissue sarcomas: distinct prognostic impact of MCT1 sub-cellular localization. J Transl Med (2014) 0.85
Head and neck squamous cancer stromal fibroblasts produce growth factors influencing phenotype of normal human keratinocytes. Histochem Cell Biol (2009) 0.85
Metabolic interplay between glycolysis and mitochondrial oxidation: The reverse Warburg effect and its therapeutic implication. World J Biol Chem (2015) 0.85
Molecular pathways: trafficking of metabolic resources in the tumor microenvironment. Clin Cancer Res (2015) 0.85
Prognostic significance of monocarboxylate transporter 4 expression in patients with colorectal cancer. Exp Ther Med (2011) 0.84
RNA interference targeting CD147 inhibits the proliferation, invasiveness, and metastatic activity of thyroid carcinoma cells by down-regulating glycolysis. Int J Clin Exp Pathol (2015) 0.84
The relationship between tumour budding, the tumour microenvironment and survival in patients with invasive ductal breast cancer. Br J Cancer (2015) 0.83
Herbal compound "Songyou Yin" attenuates hepatoma cell invasiveness and metastasis through downregulation of cytokines secreted by activated hepatic stellate cells. BMC Complement Altern Med (2013) 0.82
Linking vitamin B1 with cancer cell metabolism. Cancer Metab (2013) 0.82
The MARCH family E3 ubiquitin ligase K5 alters monocyte metabolism and proliferation through receptor tyrosine kinase modulation. PLoS Pathog (2011) 0.82
Catalysis and pH control by membrane-associated carbonic anhydrase IX in MDA-MB-231 breast cancer cells. J Biol Chem (2011) 0.82
Modeling community-wide molecular networks of multicellular systems. Bioinformatics (2011) 0.81
Glucose deprivation increases nuclear DNA repair protein Ku and resistance to radiation induced oxidative stress in human cancer cells. Cell Biochem Funct (2009) 0.81
Critical transitions in a game theoretic model of tumour metabolism. Interface Focus (2014) 0.81
Effect of hypoxia inducible factor-1 antisense oligonucleotide on liver cancer. Int J Clin Exp Med (2015) 0.80
Regression of Dalton's lymphoma in vivo via decline in lactate dehydrogenase and induction of apoptosis by a ruthenium(II)-complex containing 4-carboxy N-ethylbenzamide as ligand. Invest New Drugs (2008) 0.80
TRP channels and STIM/ORAI proteins: sensors and effectors of cancer and stroma cell migration. Br J Pharmacol (2014) 0.80
CD147 expression in advanced cutaneous squamous cell carcinoma. J Cutan Pathol (2012) 0.79
Identification of functional metabolic biomarkers from lung cancer patient serum using PEP technology. Biomark Res (2016) 0.78
Nutraceuticals as potential therapeutic agents for colon cancer: a review. Acta Pharm Sin B (2014) 0.78
The herbal compound Songyou Yin (SYY) inhibits hepatocellular carcinoma growth and improves survival in models of chronic fibrosis via paracrine inhibition of activated hepatic stellate cells. Oncotarget (2015) 0.78
The stromal genome heterogeneity between breast and prostate tumors revealed by a comparative transcriptomic analysis. Oncotarget (2015) 0.78
Bead Based Proteome Enrichment Enhances Features of the Protein Elution Plate (PEP) for Functional Proteomic Profiling. Proteomes (2015) 0.78
Crucial residue involved in L-lactate recognition by human monocarboxylate transporter 4 (hMCT4). PLoS One (2013) 0.78
Serum lactate dehydrogenase levels as a predictive marker of oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer. Int J Med Sci (2014) 0.77
Does a similar metabolic reprogramming occur in fe-deficient plant cells and animal tumor cells? Front Plant Sci (2012) 0.77
Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and cellular phenotypes in prostate cancer. Oncotarget (2015) 0.77
Metabolomics in bladder cancer: a systematic review. Int J Clin Exp Med (2015) 0.77
RPS7 inhibits colorectal cancer growth via decreasing HIF-1α-mediated glycolysis. Oncotarget (2016) 0.77
Dynamic scenario of metabolic pathway adaptation in tumors and therapeutic approach. Oncoscience (2015) 0.77
Molecular characterization of Gleason patterns 3 and 4 prostate cancer using reverse Warburg effect-associated genes. Cancer Metab (2016) 0.77
Fusion between cancer cells and myofibroblasts is involved in osteosarcoma. Oncol Lett (2011) 0.76
Role of stromal-epithelial interaction in the formation and development of cancer cells. Cancer Microenviron (2013) 0.76
Expression and role of GLUT-1, MCT-1, and MCT-4 in malignant pleural mesothelioma. Virchows Arch (2012) 0.76
Fibroblast phenotypes in different lung diseases. J Cardiothorac Surg (2014) 0.76
Recapitulating the Tumor Ecosystem Along the Metastatic Cascade Using 3D Culture Models. Front Oncol (2015) 0.76
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A (2003) 13.00
Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol (2008) 10.28
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41
Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol (2005) 6.44
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol (2006) 6.23
Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem (2004) 5.05
hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res (2008) 4.84
HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell (2002) 4.82
Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med (2011) 3.82
Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis. Nanomedicine (2011) 3.79
How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature (2012) 3.77
miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell (2010) 3.27
microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res (2011) 3.25
NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol (2003) 3.19
Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol (2010) 3.07
Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res (2003) 2.93
Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood (2005) 2.91
Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia (2002) 2.90
HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell (2005) 2.82
Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res (2009) 2.58
Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev (2007) 2.56
Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. J Pathol (2011) 2.45
Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells. Cell Metab (2012) 2.43
Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res (2002) 2.31
Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res (2007) 2.31
Activating transcription factor 4. Int J Biochem Cell Biol (2007) 2.26
HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol (2010) 2.24
Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res (2005) 2.16
Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res (2002) 2.13
Prognostic factors in patients presenting with pleural effusion revealing malignancy. Respiration (2014) 2.10
Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res (2003) 2.08
Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res (2007) 2.06
MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU. PLoS One (2010) 2.05
The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. Cancer Res (2009) 2.03
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci U S A (2011) 2.01
Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res (2003) 1.99
hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer (2010) 1.95
Hypoxia response and microRNAs: no longer two separate worlds. J Cell Mol Med (2008) 1.93
Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res (2006) 1.92
Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol (2003) 1.92
Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle (2004) 1.90
Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res (2002) 1.84
Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res (2004) 1.83
New mechanism for Notch signaling to endothelium at a distance by Delta-like 4 incorporation into exosomes. Blood (2010) 1.82
MicroRNA-10b and breast cancer metastasis. Nature (2008) 1.80
DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res (2011) 1.78
Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications. Front Biosci (Landmark Ed) (2009) 1.76
Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells. Microvasc Res (2007) 1.75
Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines. Cancer Res (2004) 1.75
Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res (2002) 1.74
Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev Mol Med (2009) 1.74
Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway--a report of the Tumour Angiogenesis Research Group. J Clin Oncol (2006) 1.74
Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys (2002) 1.74
Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One (2011) 1.72
Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin Exp Metastasis (2005) 1.71
Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia. Blood (2009) 1.70
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. J Natl Cancer Inst (2013) 1.68
Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer. Cancer Res (2002) 1.68
Hypoxia-induced genetic instability--a calculated mechanism underlying tumor progression. J Mol Med (Berl) (2006) 1.66
Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J Clin Invest (2004) 1.65
Delta-like ligand 4-notch blockade and tumor radiation response. J Natl Cancer Inst (2011) 1.62
Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma. Neoplasia (2005) 1.62
Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data. Lancet Oncol (2007) 1.61
Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res (2003) 1.60
Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res (2004) 1.59
Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. Clin Cancer Res (2006) 1.58
GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer (2003) 1.56
A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res (2004) 1.56
Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer. J Pathol (2003) 1.56
VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer (2004) 1.55
Bone morphogenetic protein 2 (BMP-2) and induction of tumor angiogenesis. J Cancer Res Clin Oncol (2005) 1.55
Acquired reactive perforating collagenosis: current status. J Dermatol (2010) 1.54
Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer. J Biol Chem (2002) 1.53
The role of carbonic anhydrase 9 in regulating extracellular and intracellular ph in three-dimensional tumor cell growths. J Biol Chem (2009) 1.53
Histological quantitation of tumour angiogenesis. APMIS (2004) 1.52
Angiogenesis in endocrine tumors. Endocr Rev (2003) 1.50
Overexpression of POLQ confers a poor prognosis in early breast cancer patients. Oncotarget (2010) 1.49
c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. Cancer Res (2004) 1.48
Lactate dehydrogenase isoenzymes 1 and 5: differential expression by neoplastic and stromal cells in non-small cell lung cancer and other epithelial malignant tumors. Tumour Biol (2003) 1.47
Transcriptional profiling of human cord blood CD133+ and cultured bone marrow mesenchymal stem cells in response to hypoxia. Stem Cells (2006) 1.47
Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy. Clin Cancer Res (2011) 1.46